A Pfizer-branded vaccine adapted to Omicron will be available next spring. In an interview published by the Swiss newspaper in German viewSabine Bruckner, head of Pfizer Switzerland, explains that the pharmaceutical group is working on two fronts: studying the effectiveness of the current vaccine against currently emerging variants, and a new version of the product. What can be said at the moment – he highlights – is that, after the recall, in adults the protection against the disease caused by Omicron is 25 times higher.
Omicron variant, everything we know so far: symptoms, evolution and therapies
